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Abstract: Sphingosine kinase 1 (SPHK1) has been found to be upregulated in many different types of human malig-
nancy and plays a crucial role in cancer development and progression. However, the potential of SPHK1 to act as a 
predictive and prognostic biomarker in breast cancer remains to be clarified. In the present study, SPHK1 expression 
was evaluated in breast cancer cell lines and 224 breast cancer tissue samples using immunohistochemical stain-
ing. Compared to the normal mammary epithelial cell line MCF-10A, SPHK1 mRNA and protein expression levels 
increased in the breast cancer cell lines SK-BR-3, MDA-MB-231, MDA-MB-436, and MCF-7. Immunohistochemical 
staining revealed SPHK1 expression to be significantly increased in breast cancer tissue compared to normal breast 
tissue, with 85 (37.9%) of the 224 invasive ductal carcinomas (IDC) exhibiting high SPHK1 expression. High SPHK1 
expression in IDC showed a significant association with higher histological grade, distant metastasis, and triple 
negativity, and was shown to be an independent predictor for distant metastasis development. In addition, patients 
with high SPHK1 expression had significantly lower progression-free survival and overall survival rates compared to 
those with low SPHK1 expression. Our data suggest that SPHK1 is involved in the development and progression of 
breast cancer and can serve as a potential predictive biomarker of distant metastasis and patient outcome.
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Introduction
Breast cancer is one of the most commonly 
diagnosed cancers among females, accounting 
for approximately 30% of all new cancer cases 
[1]. In the Republic of Korea, breast cancer is 
the second most common cancer in females 
[2]. The majority of breast cancer patient 
deaths occur after the cancer metastasizes to 
distant organs and becomes a systemic dis-
ease. The metastatic potential of breast cancer 
cells is determined by complex and specific 
genetic alterations leading to a gain and/or loss 
of function, which enable cancer cell survival, 
proliferation, migration out of the primary site, 
and invasion of the host’s blood or lymphatic 
vasculature. In turn, this provides cancer cells 
access and a conduit to metastasize [3]. 
Although many researchers have suggested 
potential biomarkers to predict the develop-
ment of breast cancer metastasis, no reliable 
biomarker has been identified to date. There is 
therefore an urgent need to establish novel pre-
dictive indicators to identify patients at higher 
risk of developing metastasis. This would also 
help enable oncologists with tailoring personal-
ized therapeutic strategies for patients in order 
to improve their survival [4].
An emerging area of investigation within lipid 
research has been the role of sphingolipid 
metabolites in cancer etiology and pathogene-
sis [5]. A number of studies have established 
the roles of various enzymes involved in sphin-
golipid metabolism, of sphingolipid-binding pro-
teins, and of transmembrane transporters in 
human cancers [6]. Among these proteins, 
members of the sphingosine kinase (SPHK) 
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family have received the most attention as key 
enzymes in cancer pathophysiology because 
their catalytic activity lies at the critical inter-
section of sphingolipid metabolism regulation 
[5]. Two functional SPHK isoenzymes, SPHK1 
and SPHK2, have been identified in humans 
[7]. Sphingosine-1-phosphate, a sphingolipid 
metabolite, plays a crucial role in various 
aspects of cellular survival, cellular growth, cel-
lular proliferation, and apoptosis [8]. SPHK1 
phosphorylates sphingosine to form sphingo-
sine-1-phosphate, so as to prevent apoptosis 
and stimulate cellular proliferation and angio-
genesis [5, 9].
SPHK1 expression is upregulated in the can-
cers of many human organs, including the ova-
ries [10], uterine cervix [5], colon [11, 12], 
stomach [9], lung [13], head and neck [8], and 
brain [14, 15]. Previous studies have shown 
that SPHK1 is an oncogenic enzyme that is acti-
vated in close association with antiapoptotic 
activity, proliferation, survival, and transforma-
tion of tumor cells [11, 14, 16-18]. Multiple 
lines of evidence indicate that SPHK1 is 
involved in cancer development, progression, 
and metastasis, as well as neovascularization 
in the tumor microenvironment [19]. However, 
investigations of SPHK1 expression in breast 
cancer are very limited. In this study, we exam-
ined SPHK1 mRNA and protein expression lev-
els in breast cancer cell lines. The expression 
pattern of SPHK1 in breast cancer tissue sam-
ples was further analyzed using a tissue micro-
array technique and immunohistochemical 
staining. In addition, we investigated the asso-
ciation between SPHK1 expression and the 
clinicopathological characteristics and out-
comes of breast cancer patients. Our observa-
tions suggest SPHK1 is involved in breast can-
cer development and progression, and is a 
potential prognostic biomarker for patients 
with breast cancer.
Materials and methods
Cell lines
The normal human mammary epithelial cell line 
MCF-10A and the human breast cancer cell 
lines SK-BR-3, MDA-MB-231, MDA-MB-436, 
and MCF-7 were purchased from the American 
Type Culture Collection (Manassas, VA, USA) 
and maintained in Dulbecco’s modified Eagle 
medium (DMEM) or Roswell Park Memorial 
Institute (RPMI) 1640 medium supplemented 
with 10% heat-inactivated fetal bovine serum 
(FBS), penicillin (100 U/mL), and streptomycin 
(100 μg/mL; Gibco, Life Technologies, Grand 
Island, NY, USA). All cell lines were cultured at 
37°C in a humidified atmosphere of 5% carbon 
dioxide.
cDNA synthesis
RNase-free DNase I treatment was carried out 
to remove contaminating genomic DNA from 
purified total RNA. Isolated total RNA was dilut-
ed to 1 mg/mL with sterile diethyl pyrocarbon-
ate-treated water and 2.5 mL was added to 
reactions containing 1× DNase I buffer and 1 U 
DNase I (final volume, 10 mL). After incubation 
at 37°C for 30 min, the reactions were stopped 
by incubating at 70°C for 10 min. DNase 
I-treated RNA was reverse-transcribed into 
first-strand cDNA using random primers. DNase 
I-treated RNA (1 μg) and random primers (250 
ng) were mixed in a 0.5 mL polymerase chain 
reaction (PCR) tube, brought to 11 mL with ster-
ile diethyl pyrocarbonate-treated water, heated 
at 65°C for 5 min, and chilled quickly on ice. 
Other reagents were added to the 20 mL total 
reaction volume at the following final concen-
trations: 1× First-Strand Buffer, 10 mM dithio-
threitol, 0.5 mM each dNTP, and 200 U 
Superscript II Reverse Transcriptase (Invitrogen, 
Carlsbad, CA, USA). Reactions were incubated 
at 42°C for 1 h, heated to 70°C for 10 min, and 
the products subsequently stored at -20°C.
Quantitative real-time reverse-transcriptase 
PCR
Total RNA was isolated using TRI Reagent 
(Molecular Research Center, Cincinnati, OH, 
USA) and used for cDNA synthesis with a 
ReverTra Ace qPCR RT kit (Toyobo, Osaka, 
Japan). The resulting amount of cDNA was 
determined spectrophotometrically was and 
thereafter used for quantitative real-time 
reverse-transcriptase PCR (qRT-PCR) using the 
Bio-Rad CFX96 Real-Time PCR Detection 
System (Bio-Rad Laboratories, Hercules, CA, 
USA) with a C1000 Thermal Cycler (Bio-Rad 
Laboratories). PCR was carried out in a 20 μL 
reaction containing 0.5 μM of each primer, 10 
μL of 2× SsoAdvanced SYBR Green Supermix 
(Bio-Rad Laboratories), and 2 μL of template 
cDNA. PCR for SPHK1 and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) were ini-
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tiated with a denaturing step at 95°C for 3 min, 
followed by 40 cycles at 95°C for 30 s and 
60°C for 30 s. Amplification patterns were ana-
lyzed and threshold cycle numbers (Ct) deter-
mined for each sample using CFX Manager 
Software (Bio-Rad Laboratories). The ΔΔCt 
method was used to calculate relative target 
gene expression after normalization to β-actin 
[20]. Amplification of the target gene was con-
firmed by melting curve analysis and target 
amplicon size was confirmed by agarose gel 
electrophoresis. Each sample was assayed in 
triplicate.
Western blot analysis
Cells (5×104 cells/well) in 6-well plates were 
incubated at 37°C in 5% CO2 in DMEM or RPMI 
containing 10% heat-inactivated FBS. Whole-
cell lysates were prepared in radioimmunopre-
cipitation assay buffer [50 mM Tris-hydrogen 
chloride, pH 8, 150 mM sodium chloride, 1% 
NP-40, 0.5% sodium deoxycholate, and 0.1% 
sodium dodecyl sulphate] containing protease 
inhibitors (cOmplete Protease Inhibitor Cocktail 
Tablet; Roche Applied Science, Basel, Switzer- 
land), and cleared by microcentrifugation 
(10,000×g for 20 min at 4°C). The resulting 
lysate was assessed for protein concentration, 
and 20-30 μg of each protein sample was 
resolved using 12% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (Bio-Rad 
Laboratories) and electroblotted onto nitrocel-
lulose membranes (GE Healthcare, Little 
Chalfont, UK). After 1 h incubation in blocking 
solution (5% non-fat dry milk in Tris-buffered 
saline with Tween; Pierce, Rockford, IL, USA), 
the membranes were exposed to the following 
primary antibodies overnight at 4°C: anti-
SPHK1 antibody (1:200, polyclonal; Abcam, 
Cambridge, MA, USA) and anti-GAPDH (1:1,000; 
Abcam). The blots were washed three times in 
Tris-buffered saline with Tween and incubated 
with the horseradish peroxidase-conjugated 
secondary antibody (Cell Signaling Technology, 
Beverly, MA, USA) for 1 h at room temperature. 
Protein bands were visualized using enhanced 
chemiluminescence reagents (iNtRON Biotech- 
nology, Seongnam, Republic of Korea).
Tissue specimens
This study (2017-08-017) was reviewed and 
approved by the Institutional Review Board of 
Kangbuk Samsung Hospital (Seoul, Republic of 
Korea). We selected 224 cases of invasive duc-
tal carcinoma (IDC) and 35 cases of ductal car-
cinoma in situ (DCIS) from archival cases in 
Kangbuk Samsung Hospital (Seoul, Republic of 
Korea). Twenty normal breast tissue samples 
were used as controls. Tissues resected by sur-
geons were initially examined by pathologists 
before fixation in 10% neutral-buffered forma-
lin. After fixation for 12-24 h, the tissues were 
thoroughly examined macroscopically and sec-
tioned. After processing with an automatic tis-
sue processor, the sections were embedded in 
paraffin blocks and 4 μm thick slices were cut 
from each formalin-fixed, paraffin-embedded 
tissue block using a rotary microtome. Tissue 
slices were subsequently stained with hema-
toxylin and eosin using an automatic staining 
instrument. After staining, the slides were cov-
ered with a glass coverslip and sent to two 
board-certified pathologists who examined the 
slides by light microscopy and made definitive 
pathological diagnoses. Clinical and pathologi-
cal information was obtained from electrical 
medical information systems and pathology 
reports. The clinicopathological characteristics 
reviewed included age of the patients, histo-
logical grade, tumor size, pathological T stage 
(pT), pathological N stage (pN), distant metas-
tasis, stage group, lymphovascular invasion, 
extensive intraductal component, estrogen 
receptor (ER) status, progesterone receptor 
(PR) status, human epidermal growth factor 
receptor 2 (HER2) status, triple negativity, 
tumor recurrence, follow-up period, and death 
from IDC. Histological grades were assigned 
based on the modified Bloom-Richardson grad-
ing system [21].
Tissue microarray construction
Tissue microarray blocks were constructed as 
previously described [4]. Briefly, all hematoxylin 
and eosin-stained slides were reviewed thor-
oughly and the two most representative tumor 
areas were marked on the corresponding for-
malin-fixed, paraffin-embedded tissue blocks. 
Two 2 mm diameter tissue cores were obtained 
from each block and manually arrayed into 
recipient tissue microarray blocks. The assem-
bly was held in an X-Y position guide, with a 1 
mm increment between the individual cores, 
and the instrument was used to create holes in 
a recipient block with defined array cores. The 
appropriate needle was used to transfer the 
cores into the recipient block. The percentage 
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of tumor volume in each core was greater than 
70%. A pair of tissue microarray blocks was 
made for each case.
Immunohistochemical staining
The 4 μm thick, formalin-fixed, paraffin-embed-
ded slices were deparaffinized, dehydrated 
with xylene, and then rehydrated in a graded 
series of alcohol solutions. Immunohisto- 
chemical staining was performed using an 
automatic immunostainer, with a compact poly-
mer method (Bond Intense Detection Kit, Leica 
Biosystems, Newcastle upon Tyne, UK), accord-
ing to the manufacturer’s recommendations [4, 
5, 22-26]. The primary antibodies used were 
specific for ER (1:200, clone SP1, Lab Vision 
Corporation, Fremont, CA, USA), PR (1:200, 
clone PgR 636, Dako, Glostrup, Denmark), HE- 
R2 (1:200, clone SP3, Lab Vision Corporation), 
and SPHK1 (1:100, polyclonal, Abgent, Inc., 
San Diego, CA, USA). After chromogenic visual-
ization using peroxidase/DAB (EnVision+ 
Detection Systems, Dako), slices were counter-
stained with hematoxylin and coverslipped. The 
expression status of ER and PR was assessed 
using the Allred scoring method [27]. HER2 
expression status was evaluated using Ameri- 
can Society of Clinical Oncology/College of 
American Pathologists Guideline Recommen- 
dations [28].
Interpretation of immunohistochemical stain-
ing
The degree of SPHK1 expression, as deter-
mined by immunohistochemical staining, was 
evaluated by combining scores for the propor-
tion of positively stained cancer cells and stain-
ing intensity, as previously described [5, 15, 
29]. Briefly, the area of stained cancer cells 
was scored as follows: 0, no staining; 1, 1-9%; 
2, 10-49%; and 3, ≥ 50% of all cancer cells. 
Staining intensity was determined as follows: 0, 
absent; 1, weak; 2, moderate; and 3, strong. 
The final score was calculated as the product of 
the proportion score and intensity score, result-
ing in scores of 0, 1, 2, 3, 4, 6, and 9. The opti-
mal cutoff value for high and low SPHK1 expres-
sion levels were chosen on the basis of distri-
bution of the staining results and a measure of 
heterogeneity with the log-rank test with 
respect to overall survival (OS). A final score of 
4 or more was used to define tumors with high 
SPHK1 expression, and a final score less than 
4 indicated low SPHK1 expression. All slides 
were examined and scored by two board-certi-
fied pathologists, who were blinded to the clini-
copathological data and patient identity. 
Disagreements between the two pathologists 
were resolved by consensus.
Statistical analysis
We used the unpaired student’s t-test to com-
pare the expression levels of SPHK1 between 
normal mammary epithelial and breast cancer 
cell lines. The chi-square test, Fisher’s exact 
test, or linear-by-linear association test were 
performed to determine the association 
between SPHK1 expression status and clinico-
pathological characteristics. Multivariate logis-
tic regression analysis with a backward step-
wise elimination method was used to identify 
the independent predictors of distant metasta-
sis. Univariate and multivariate survival analy-
ses were used to examine the prognostic sig-
nificance of SPHK1 expression. Curves for OS 
and recurrence-free survival (RFS) were drawn 
according to the Kaplan-Meier method and dif-
ferences were analyzed by applying the log-
rank test for univariate survival analysis. 
Multivariate survival analysis was performed 
for parameters that achieved statistical signifi-
cance in univariate survival analysis, using the 
Cox proportional hazards model (95% confi-
dence interval) with a backward stepwise elimi-
nation method. Statistical analyses were per-
formed using PASW Statistics for Windows (ver-
sion 18.0; IBM SPSS Inc., Chicago, IL, USA). 
Statistical significance was defined as a P-value 
less than 0.05.
Figure 1. SPHK1 expression in breast cancer cell 
lines. A. Western blot for SPHK1. B. Normalized 
SPHK1 mRNA expression ratio analyzed by qRT-PCR. 
*P < 0.05 versus MCF-10A.
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Results
Patient demographics
The patients’ age ranged from 28-92 years 
(median, 51 years). Among 224 patients, 57 
(25.4%), 93 (41.5%), and 74 (33.0%) had an IDC 
according to the modified Bloom-Richardson 
grade of 3, 2, and 1, respectively; 112 (50.0%), 
101 (45.1%), and 11 (4.9%) had pT1, pT2, and 
pT3 disease, respectively; 104 (46.4%) patients 
had lymph node metastasis; 65 (62.5%), 21 
(20.2%), and 18 (17.3%) had pN1, pN2, and 
pN3 disease, respectively; and 76 (33.9%), 106 
(47.3%), and 42 (18.8%) had stage I, II, and III 
disease, respectively. Twenty (8.9%) patients 
developed distant metastasis in the central 
nervous system, lung, liver, pancreas, adrenal 
gland, peritoneum, or bone. Lymphovascular 
invasion was detected in 89 (39.7%) patients. 
Forty (17.9%) patients exhibited an extensive 
intraductal component and 30 (13.4%) patients 
had triple negative tumors. The median follow-
up of survivors was 63 months. Nine (4.0%) 
patients died by the time of the final follow-up, 
with a median time of 48 months from surgery 
to death. One hundred and sixteen (51.8%) 
patients survived more than 5 years. Tumor 
recurrence during the follow-up period occurred 
in 30 (13.4%) patients.
Sphingosine kinase 1 expression in breast 
cancer cells
SPHK1 was expressed at varying levels in dif-
ferent breast cancer cell lines. The breast can-
cer cell lines SK-BR-3, MDA-MB-231, MDA-
MB-436, and MCF-7 exhibited increased 
SPHK1 expression compared to the normal 
mammary epithelial cell line MCF-10A (Figure 
1A). Consistent with these findings, SK-BR-3 
(normalized expression ratio, 1.7), MDA-
Figure 2. Immunohistochemical expression of SPHK1 in normal and cancerous breast tissue. Negative SPHK1 ex-
pression in (A) the ductal epithelial cells of normal breast, (B) ductal carcinoma in situ, and (C and D) invasive ductal 
carcinoma. High SPHK1 expression in (E-G) ductal carcinoma in situ and (H-J) invasive ductal carcinoma (compact 
polymer method).
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MB-231 (normalized expression ratio, 1.5), 
MDA-MB-436 (normalized expression ratio, 
3.4), and MCF-7 (normalized expression ratio, 
2.7) showed higher SPHK1 mRNA expression 
levels than MCF-10A (Figure 1B).
Sphingosine kinase-1 expression in normal 
breast tissue, ductal carcinoma in situ, and 
invasive ductal carcinoma tissues
Representative photomicrographs of SPHK1 
immunostaining in normal breast tissue, DCIS, 
and IDC are shown in Figure 2. No staining was 
observed in all 20 normal breast tissue sam-
ples. By contrast, both DCIS and IDC tissues 
exhibited SPHK1 expression of varying staining 
intensity and proportion. Seven of the 35 DCIS 
tissue samples (20%) exhibited high SPHK1 
expression, while the remaining 28 samples 
(80.0%) exhibited low SPHK1 expression. 
Among the 224 IDC tissues, 85 (37.9%) showed 
high SPHK1 expression, whereas the remaining 
137 (61.2%) had low SPHK1 expression. In 
DCIS and IDC tissues, SPHK1 expression was 
primarily observed in the cytoplasm of tumor-
ous cells, although tumor cells with strong cyto-
Table 1. Association between sphingosine kinase 1 (SPHK1) expression and clinicopathological char-
acteristics of invasive ductal carcinoma of the breast
Characteristic Total
SPHK1 expression
P-value
High (%) Low (%)
Age (years) >50 111 39 (35.1) 72 (64.9) 0.390
≤50 113 46 (40.7) 67 (59.3)
Histological grade 1 57 14 (24.6) 43 (75.4) < 0.001*
2 93 31 (33.3) 62 (66.7)
3 74 40 (54.1) 34 (45.9)
Tumor size (cm) >2.0 112 43 (38.4) 69 (61.6) 0.890
≤2.0 112 42 (37.5) 70 (62.5)
Pathological T stage pT1 112 42 (37.5) 70 (62.5) 0.213
pT2 101 34 (33.7) 67 (66.3)
pT3 11 9 (81.8) 2 (18.2)
Pathological N stage pN0 120 45 (37.5) 75 (62.5) 0.385
pN1 65 21 (32.3) 44 (67.7)
pN2 21 11 (52.4) 10 (47.6)
pN3 18 8 (44.4) 10 (55.6)
Distant metastasis Present 20 15 (75.0) 5 (25.0) < 0.001*
Absent 204 70 (34.3) 134 (65.7)
Stage group I 76 26 (34.2) 50 (65.8) 0.085
II 106 37 (34.9) 69 (65.1)
III 42 22 (52.4) 20 (47.6)
Lymphovascular invasion Present 89 39 (43.8) 50 (56.2) 0.141
Absent 135 46 (34.1) 89 (65.9)
Extensive intraductal component Present 40 12 (30.0) 28 (70.0) 0.253
Absent 184 73 (39.7) 111 (60.3)
Estrogen receptor status Negative 63 32 (50.8) 31 (49.2) 0.013*
Positive 161 53 (32.9) 108 (67.1)
Progesterone receptor status Negative 76 37 (48.7) 39 (51.3) 0.018*
Positive 148 48 (32.4) 100 (67.6)
Human epidermal growth factor receptor 2 status Negative 165 69 (41.8) 96 (58.2) 0.046*
Positive 59 16 (27.1) 43 (72.9)
Triple negativity Yes 30 19 (63.3) 11 (36.7) 0.002*
No 194 66 (34.0) 128 (66.0)
*Statistically significant.
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plasmic SPHK1 expression displayed weak-to-
moderate nuclear SPHK1 immunoreactivity. 
The frequency of high SPHK1 expression in IDC 
was significantly higher than that in DCIS (P = 
0.039) or normal breast tissue (P < 0.001). 
Similarly, the frequency of high SPHK1 expres-
sion in DCIS was significantly higher than that 
in normal breast tissue (P = 0.040).
Association between sphingosine kinase 1 
expression and clinicopathological characteris-
tics of invasive ductal carcinoma of the breast
Relationships between SPHK1 expression sta-
tus and clinicopathological characteristics of 
IDC are summarized in Table 1. Significant cor-
relations were observed between high SPHK1 
expression and higher histological grade (P < 
0.001), development of distant metastasis (P < 
0.001), ER negativity (P = 0.013), PR negativity 
(P = 0.018), HER2 negativity (P = 0.046), and 
triple negativity (P = 0.002). There were margin-
ally significant associations between high 
SPHK1 expression and advanced stage (P = 
0.085). Associations between SPHK1 expres-
sion and patients’ age, tumor size, pT, pN, stage 
group, lymphovascular invasion, and extensive 
intraductal component were not statistically 
significant.
Factors independently predicting distant me-
tastasis in patients with invasive ductal carci-
noma of the breast
Relationships between distant metastasis, clin-
icopathological characteristics, and SPHK1 
expression are summarized in Table 2. Higher 
Table 2. Factors predicting distant metastasis in patients with invasive ductal carcinoma of the breast
Characteristic
Univariate Multivariate
Distant metastasis
P-value P-value Relative risk (95% 
confidence interval)Present 
(%) Absent (%)
Age (years) >50 6 (5.4) 105 (94.6) 0.067 Not applicable
≤50 14 (12.4) 99 (87.6)
Histological grade 1 2 (3.5) 55 (96.5) 0.092 Not applicable
2 9 (9.7) 84 (90.3)
3 9 (12.2) 65 (87.8)
Tumor size (cm) >2.0 12 (10.7) 100 (89.3) 0.349 Not applicable
≤2.0 8 (7.1) 104 (92.9)
Pathological T stage pT1 8 (7.1) 104 (92.9) 0.017* 0.699 1.218 (0.447-3.321)
pT2 7 (6.9) 94 (93.1)
pT3 5 (45.5) 6 (54.5)
Pathological N stage pN0 7 (5.8) 113 (94.2) 0.016* 0.085 2.383 (0.888-6.396)
pN1 5 (7.7) 60 (92.3)
pN2 5 (23.8) 16 (76.2)
pN3 3 (16.7) 15 (83.3)
Lymphovascular invasion Present 12 (13.5) 77 (86.5) 0.052 Not applicable
Absent 8 (5.9) 127 (94.1)
Extensive Intraductal component Present 1 (2.5) 39 (97.5) 0.138 Not applicable
Absent 19 (10.3) 165 (89.7)
Estrogen receptor status Negative 13 (8.1) 148 (91.9) 0.474 Not applicable
Positive 7 (11.1) 56 (88.9)
Progesterone receptor status Negative 9 (6.1) 139 (93.9) 0.037* 0.135 2.103 (0.794-5.573)
Positive 11 (14.5) 65 (85.5)
Human epidermal growth factor receptor 2 status Negative 4 (6.8) 55 (93.2) 0.603 Not applicable
Positive 16 (9.7) 149 (90.3)
Triple negativity Yes 5 (16.7) 25 (83.3) 0.110 Not applicable
No 15 (7.7) 179 (92.3)
Sphingosine kinase 1 expression High 15 (17.6) 70 (83.3) < 0.001* 0.001* 5.841 (2.024-16.858)
Low 5 (3.6) 134 (96.4)
*Statistically significant.
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pT (P = 0.017), higher pN (P = 0.016), PR nega-
tivity (P = 0.037), and high SPHK1 expression 
were found to closely associate with distant 
metastasis in patients with IDC. To identify the 
factors that independently predict the develop-
ment of distant metastasis, these four covari-
ates were entered into a multivariate logistic 
regression analysis. High SPHK1 expression 
was the only independent predictive factor for 
distant metastasis (P = 0.001, relative risk = 
5.841; 95% confidence interval = 2.024-
16.858); pT, pN, and PR status did not indepen-
dently predict the development of distant 
metastasis.
Table 3. Factors predicting shorter overall survival of patients with invasive ductal carcinoma of the 
breast
Characteristic
Overall survival
Univariate Multivariate
P-value P-value Hazard ratio (95% confidence interval)
Age (years): >50 vs. ≤50 0.747 Not applicable
Histological grade: 3-2 vs. 1 0.069 Not applicable
Pathological T stage: pT2-3 vs. pT1 0.026* 0.169 4.329 (0.536-34.999)
Pathological N stage: pN1-3 vs. pN0 0.012* 0.090 6.157 (0.752-50.411)
Distant metastasis: Present vs. absent < 0.001* < 0.001* 11.909 (3.145-45.101)
Stage group: III vs. I-II < 0.001* 0.765 1.341 (0.196-9.187)
Lymphovascular invasion: Present vs. absent 0.024* 0.598 1.582 (0.287-8.712)
Estrogen receptor status: Negative vs. positive 0.213 Not applicable
Progesterone receptor status: Negative vs. positive 0.029* 0.605 1.564 (0.286-8.543)
Human epidermal growth factor receptor 2 status: Negative vs. positive 0.248 Not applicable
Triple negativity: Yes vs. no 0.029* 0.096 3.409 (0.804-14.455)
Sphingosine kinase 1 expression: High vs. low 0.048* 0.671 1.411 (0.287-6.937)
*Statistically significant.
Figure 3. Kaplan-Meier curves illustrating (A) overall survival and (B) recurrence-free survival among patients with 
invasive ductal carcinoma with respect to SPHK1 expression status. Patients whose tumors showed high SPHK1 
expression had shorter overall survival times (P = 0.048) and recurrence-free survival (P < 0.001) compared to 
those showing low SPHK1 expression (log-rank test).
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Prognostic significance of sphingosine kinase 
1 expression in patients with invasive ductal 
carcinoma of the breast
Univariate analysis for OS revealed that higher 
pT (P = 0.026), lymph node metastasis (P = 
0.012), distant metastasis (P < 0.001), 
advanced stage (P < 0.001), lymphovascular 
invasion (P = 0.024), PR negativity (P = 0.029), 
triple negativity (P = 0.029), and high SPHK1 
expression (P = 0.048) significantly predicted 
poor OS (Table 3). The 5-year OS rates were 
97.7% for patients with SPHK1-high IDC and 
89.4% for patients with SPHK1-low IDC (Figure 
3). Multivariate analysis of OS was performed 
using pT, lymph node metastasis, distant 
metastasis, stage group, lymphovascular inva-
sion, PR status, triple negativity, and SPHK1 
expression status as covariates. Only distant 
metastasis independently predicted OS (P < 
0.001; Table 3). SPHK1 expression by itself did 
not predict OS (P = 0.671).
Univariate analysis of RFS revealed that higher 
histological grade (P = 0.038), higher pT (P = 
0.017), distant metastasis (P < 0.001), 
advanced stage (P = 0.044), PR negativity (P = 
0.019), triple negativity (P = 0.003), and high 
SPHK1 expression (P < 0.001) were significant 
predictors of poor RFS (Table 4). The respective 
3- and 5-year RFS rates were 96.9% and 93.4% 
for patients with SPHK1-high IDC, and 80.6% 
and 73.2% for patients with SPHK1-low IDC 
(Figure 3). Multivariate analysis of RFS revealed 
that higher pT (P = 0.047), distant metastasis 
(P < 0.001), triple negativity (P = 0.043), and 
high SPHK1 expression (P = 0.038) were inde-
pendent predictors of shorter RFS (Table 4). 
The hazard ratio of high SPHK1 expression for 
RFS (2.426, 95% confidence interval = 1.052-
5.595) was higher than that of high pT (2.300, 
95% confidence interval = 1.012-5.228) and 
triple negativity (2.357, 95% confidence inter-
val = 1.027-5.408).
Discussion
In the present study, we analyzed the immuno-
histochemical expression of SPHK1 in human 
breast cancer cells and tissues. Consistent 
with previous reports [5, 9, 15, 30-32], SPHK1 
expression was significantly increased in breast 
cancer cells and tissues compared with normal 
mammary epithelial cells and breast tissues. In 
our study, 37.9% (85/224) of IDC tissue sam-
ples showed high SPHK1 expression, with sig-
nificant differences in the frequency of high 
SPHK1 expression between DCIS and normal 
breast tissue (P = 0.040), and between IDC and 
DCIS (P = 0.039). These findings indicate that 
SPHK1 expression is upregulated in breast 
cancer and implicate SPHK1 as a potential 
diagnostic biomarker for breast cancer.
We examined the association between SPHK1 
expression and the clinicopathological charac-
teristics of patients with IDC and found a signifi-
cant relationship between high SPHK1 expres-
Table 4. Factors predicting shorter recurrence-free survival of patients with invasive ductal carcinoma 
of the breast
Characteristic
Recurrence-free survival
Univariate Multivariate
P-value P-value Hazard ratio (95% confidence interval)
Age (years): >50 vs. ≤50 0.338 Not applicable
Histological grade: 3-2 vs. 1 0.038* 0.529 1.482 (0.435-5.054)
Pathological T stage: pT2-3 vs. pT1 0.017* 0.047* 2.300 (1.012-5.228)
Pathological N stage: pN1-3 vs. pN0 0.173 Not applicable
Distant metastasis: Present vs. absent < 0.001* < 0.001* 10.189 (4.623-22.453)
Stage group: III vs. I-II 0.044* 0.615 0.762 (0.264-2.198)
Lymphovascular invasion: Present vs. absent 0.174 Not applicable
Estrogen receptor status: Negative vs. positive 0.132 Not applicable
Progesterone receptor status: Negative vs. positive 0.019* 0.913 0.948 (0.369-2.482)
Human epidermal growth factor receptor 2 status: Negative vs. positive 0.353 Not applicable
Triple negativity: Yes vs. no 0.003* 0.043* 2.357 (1.027-5.408)
Sphingosine kinase 1 expression: High vs. low < 0.001* 0.038* 2.426 (1.052-5.595)
*Statistically significant.
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sion and aggressive oncogenic behaviors, 
including higher histological grade, distant 
metastasis, ER negativity, PR negativity, HER2 
negativity, and triple negativity. These findings 
implicate SPHK1 as a potentially important 
contributing factor in breast cancer progres-
sion and are consistent with recent data show-
ing that increased SPHK1 expression is associ-
ated with lymph node metastasis and distant 
metastasis of breast cancer [33]. Our results 
are also in agreement with those of previous 
studies demonstrating an association between 
increased SPHK1 expression and aggressive 
oncogenic behaviors, such as larger tumor size, 
deeper invasion depth, advanced stage, worse 
histological differentiation, higher invasive 
capacity, and/or chemotherapeutic resistance 
in cervical cancer [5], head and neck cancer 
[34], thyroid cancer [29], salivary duct cancer 
[30], esophageal cancer [35], colorectal cancer 
[36], and bladder cancer [37]. Furthermore, we 
observed that high SPHK1 expression was the 
only independent factor for predicting the 
development of distant metastasis. 
The extent of primary tumor and lymph node 
metastasis is the most important prognostic 
factor in breast cancer and one of the main 
determinants for predicting tumor progression 
and aggressive oncogenic behavior. Surpri- 
singly, in this study, the relative risk of distant 
metastasis associated with high SPHK1 
expression (5.841, 95% confidence interval = 
2.024-16.858) was higher than the risk associ-
ated with pT (1.218, 95% confidence interval = 
0.447-3.321) and pN (2.383, 95% confidence 
interval = 0.888-6.396). To the best of our 
knowledge, the use of SPHK1 expression to 
predict distant metastasis has not been previ-
ously investigated. Our data suggest that 
SPHK1 immunostaining provides clinically use-
ful information for patients with IDC of the 
breast and that SPHK1 expression is a strong 
and novel predictive biomarker for the identifi-
cation of patients at high risk of developing dis-
tant metastasis.
We further observed that IDC patients whose 
tumors showed high SPHK1 expression had 
shorter OS and RFS than those with SPHK1-low 
tumors. Moreover, high SPHK1 expression was 
an independent factor for predicting shorter 
recurrence-free survival of patients with IDC. 
These results are in line with those of a recent 
study demonstrating that increased SPHK1 
expression is associated with both decreased 
overall and disease-specific survival of patients 
with IDC, and independently predicts worse OS 
[33]. The prognostic significance of SPHK1 has 
been documented in several types of human 
malignancy, including glioblastoma [14], head 
and neck cancer [8], salivary duct cancer [30], 
esophageal cancer [35], gastric cancer [9], and 
colorectal cancer [36]; with all these studies 
suggesting that patients with SPHK1-high 
tumors had shorter survival times whereas 
those with SPHK1-low tumors survived longer. 
Although the traditional staging system suc-
cessfully grades patients with respect to their 
prognosis according to clinicopathological 
characteristics, it does not provide critical infor-
mation that may influence treatment strategy. 
Many biomarkers have been investigated to 
overcome the limitations of the traditional sys-
tem and have shown potential predictive signifi-
cance. However, reliable biomarkers that can 
stratify patients with IDC are substantially lim-
ited. In our analysis, high SPHK1 expression 
had a clear prognostic value for RFS in patients 
with IDC. SPHK1 expression in IDC can be used 
as a novel prognostic marker for poor outcomes 
in breast cancer patients.
In conclusion, we demonstrated that, com-
pared with normal breast tissue, SPHK1 expres-
sion was significantly upregulated in breast 
cancer tissues, and upregulated SPHK1 expres-
sion showed significant association with 
aggressive oncogenic behavior of breast can-
cer, including higher histological grade, distant 
metastasis, and hormone receptor negativity. 
High SPHK1 expression was also found to be 
an independent factor predicting the develop-
ment of distant metastasis and shorter recur-
rence-free survival. Thus, alterations in SPHK1 
expression potentially promote tumor develop-
ment, progression, and metastasis of breast 
cancer, and SPHK1 expression status may 
serve as a predictive biomarker for distant 
metastasis and patient outcomes.
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